In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study.
about
Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection modelTelavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogensIn vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infectionCurrent and novel antibiotics against resistant Gram-positive bacteriaOritavancin diphosphateMechanism of action of oritavancin and related glycopeptide antibiotics.Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria.Oritavancin: a new avenue for resistant Gram-positive bacteria.Investigational new drugs for the treatment of resistant pneumococcal infections.Anti-MRSA agents: under investigation, in the exploratory phase and clinically available.Current use of anti-infectives in dermatology.The antimicrobial armamentarium: evaluating current and future treatment options.Oritavancin--an investigational glycopeptide antibiotic.Comparative in vitro activities of AC98-6446, a novel semisynthetic glycopeptide derivative of the natural product mannopeptimycin alpha, and other antimicrobial agents against gram-positive clinical isolates.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Vancomycin resistance: are there better glycopeptides coming?A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility.Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
P2860
Q33593883-35320BE6-C365-4BEB-90BD-34B552542409Q33788308-947D06F5-5C56-4680-A328-F4174671F052Q34110412-60B4DD7F-7A05-4CB1-911D-5BE4CF4BA66FQ34937444-CAD4B493-9616-470E-8EFD-A9E1AEFF6B01Q35026521-E04CCB68-2505-4CC1-A079-FCFA3E599B92Q35057973-2933170E-C5B4-4262-9F54-BD067FDD0B7BQ35066202-65839BB6-AB57-4D3F-944D-48DA34474947Q35637071-C9436190-102E-4B6C-8616-59822314D799Q36162339-AA5BFA24-0376-4AFF-9EFD-CFA2E1C2BDF2Q36210902-85DC1855-AE03-4E83-A929-965F742A6148Q36233502-223123D5-C1BB-4014-81E7-51B3B6E7B50BQ36233506-85E66CC3-2DB1-4E7D-9FB0-0C5D89664141Q36264494-4BD9A6B3-B666-4B48-A424-55A8940297EDQ36426011-606CC496-55DC-49CF-B203-1ADA3C36C038Q36492132-5F0D98F1-2081-4508-A5A6-22A6B8F2F009Q36718474-7C140B79-20BA-4601-8517-FD764FB22B50Q37071199-3C79709D-B9D0-40A3-BA07-15ABF287D39CQ37340562-88A5EFA5-497B-436A-86CA-CBC5F9AD90D0Q37661510-54BE3782-0CE3-4BAF-890A-6C4050EBBF97Q41290708-B0017D55-3921-4C43-9A38-8E649AE0F2B2Q41493636-13FE4C42-6BD4-46E1-95D8-CAE179494D01Q42111507-2442A581-F9EF-4678-BB5C-A0D06288F4D6
P2860
In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
In vitro activities of LY33332 ...... 997 global surveillance study.
@ast
In vitro activities of LY33332 ...... 997 global surveillance study.
@en
type
label
In vitro activities of LY33332 ...... 997 global surveillance study.
@ast
In vitro activities of LY33332 ...... 997 global surveillance study.
@en
prefLabel
In vitro activities of LY33332 ...... 997 global surveillance study.
@ast
In vitro activities of LY33332 ...... 997 global surveillance study.
@en
P2093
P2860
P1476
In vitro activities of LY33332 ...... 997 global surveillance study.
@en
P2093
D A Preston
M L Zeckel
P2860
P304
P356
10.1128/AAC.44.5.1370-1374.2000
P407
P577
2000-05-01T00:00:00Z